OncoSil Medical (ASX:OSL) has filed its FDA Humanitarian Device Exemption submission for dCCA, with the agency signalling a 45-day review window.
03
Stocks in Spotlight
View all →-
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) Builds a Merchant Revenue Engine as CIO Fund Scales July 3, 2026 -
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) US$50m Partner Commitment Puts CIO Fund Re-Rate in Focus June 26, 2026 -
Growth Stocks WiseTech Global (ASX:WTC) Why the A$30 Sell-Off Could Be a Long-Term Opportunity June 23, 2026
